Jefferies Group's TGTX Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 16,000 shares of TG Therapeutics, Inc. (TGTX) worth $476,960, representing 0.00% of the portfolio. First purchased in 2023-Q1, this short-term holding has been held for 3 quarters.
Based on 13F filings, Jefferies Group has maintained this position in TGTX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 16,000 shares. Largest reduction occurred in Q2 2023, reducing 5.1 M shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's TG Therapeutics (TGTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly TG Therapeutics (TGTX) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2023 | +5.1 M | New Buy | 5.1 M | $15.04 |
| Q2 2023 | -5.1 M | Sold Out | 0 | $0.00 |
| Q4 2025 | +16,000 | New Buy | 16,000 | $29.81 |
Jefferies Group's TG Therapeutics Investment FAQs
Jefferies Group first purchased TG Therapeutics, Inc. (TGTX) in Q1 2023, acquiring 5,100,110 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held TG Therapeutics, Inc. (TGTX) for 3 quarters since Q1 2023.
Jefferies Group's largest addition to TG Therapeutics, Inc. (TGTX) was in Q1 2023, adding 5,100,110 shares worth $76.71 M.
According to the latest 13F filing for Q4 2025, Jefferies Group's firm, Jefferies Financial Group Inc., owns 16,000 shares of TG Therapeutics, Inc. (TGTX), valued at approximately $476,960.
As of the Q4 2025 filing, TG Therapeutics, Inc. (TGTX) represents approximately 0.00% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in TG Therapeutics, Inc. (TGTX) was 5,100,110 shares, as reported at the end of Q1 2023.